Loading data for CMPS — first visit, this takes a few seconds.

알림

COMPASS Pathways (CMPS)

NasdaqGS: CMPS · 실시간 가격 · USD

13.71

-0.30 (-2.14%)

종가 기준: Aug 20, 2026, 8:00 PM

13.89

+0.51%

애프터마켓: 6:07 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-2.14% (1D)

데이터 없음

매수호가	10.2
시가총액	1.91B
매출 (ttm)	n/a
순이익 (ttm)	-394.19M
	2.53
	-3.79
	n/a
	-9.64
P/B (ttm)	22.18
P/S (ttm)	n/a
실적 발표일	Nov 3, 2026

매도호가	17.56
거래량	1,149,957
평균 거래량 (20일)	3,811,619
시가	14.00
전일 종가	14.01
일중 범위	13.65 - 14.20
52주 범위	4.04 - 15.40
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CMPS 소개

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to...

[더 보기]

산업 Medical Care Facilities

섹터 Healthcare

IPO 일자 Sep 18, 2020

직원 수 156

상장 거래소 NasdaqGS

티커 CMPS

웹사이트 https://compasspathways.com

전체 기업 정보

재무 실적

2025년 COMPASS Pathways의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -287.86M로, 85.57% 증가했습니다.

재무제표

어닝 서프라이즈

COMPASS Pathways가 Aug 5, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.36 예상치 하회 -0.03, 및 12.20% 전년 대비 성장.

다음 실적 발표

COMPASS Pathways의 실적 발표 예정일은 Nov 3, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · MarketBeat

Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adj...

1주 전 · Motley Fool

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript

COMP360 shows 39% response rate; commercial launch targeted for H1 2027.

1주 전 · MarketBeat

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quart...

1주 전 · Market Exclusive

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground C...

1주 전 · Simply Wall St.

COMPASS Pathways (CMPS) Could Be 45% Below Fair Value On VA Trial Collaboration

COMPASS Pathways (NasdaqGS:CMPS) just announced a collaboration with the U.S. Department of Veterans Affairs on the PIVOT trial, a multi site study of COMP360 psilocybin in veterans with treatment res...

2 페이지 중 1

COMPASS Pathways (CMPS)